Background. Follistatin-like 3 (FSTL3) is a novel cytokine that regulates insulin sensitivity and counteracts activin/myostatin signalling. In the present study, regulation of FSTL3 in renal dysfunction was investigated in both human chronic kidney disease (CKD) and acute kidney dysfunction (AKD). Furthermore, mFSTL3 expression was analysed in insulin-sensitive tissues in a mouse model of CKD. Methods. Circulating FSTL3 was quantified by enzyme-linked immunosorbent assay in 581 patients with CKD covering the whole spectrum of estimated glomerular filtration rate (eGFR) categories from G1 to G5. Furthermore, FSTL3 was measured in 61 patients before and within 30 h after elective unilateral nephrectomy, an established model of AKD. Moreover, mFSTL3 mRNA expression was investigated in an animal CKD model, that is, eNOS À/À db/db mice, and compared with littermate controls. Results. Median circulating FSTL3 levels significantly and continuously increased with deteriorating renal function (eGFR category G1: 6.1; G2: 8.2; G3: 12.7; G4: 18.5; G5: 32.1 mg/L; P < 0.001). In both human CKD and AKD, renal dysfunction remained the strongest independent predictor of FSTL3 serum concentrations in multivariate analyses. FSTL3 was independently associated with an adverse cardiometabolic profile. In CKD mice, hepatic mFSTL3 mRNA expression was increased more than 6-fold as compared with controls. Conclusions. Circulating FSTL3 is significantly and independently associated with renal function in both patients with CKD
A B S T R A C T
Background. Follistatin-like 3 (FSTL3) is a novel cytokine that regulates insulin sensitivity and counteracts activin/myostatin signalling. In the present study, regulation of FSTL3 in renal dysfunction was investigated in both human chronic kidney disease (CKD) and acute kidney dysfunction (AKD). Furthermore, mFSTL3 expression was analysed in insulin-sensitive tissues in a mouse model of CKD. Methods. Circulating FSTL3 was quantified by enzyme-linked immunosorbent assay in 581 patients with CKD covering the whole spectrum of estimated glomerular filtration rate (eGFR) categories from G1 to G5. Furthermore, FSTL3 was measured in 61 patients before and within 30 h after elective unilateral nephrectomy, an established model of AKD. Moreover, mFSTL3 mRNA expression was investigated in an animal CKD model, that is, eNOS À/À db/db mice, and compared with littermate controls. Results. Median circulating FSTL3 levels significantly and continuously increased with deteriorating renal function (eGFR category G1: 6.1; G2: 8.2; G3: 12.7; G4: 18.5; G5: 32.1 mg/L; P < 0.001). In both human CKD and AKD, renal dysfunction remained the strongest independent predictor of FSTL3 serum concentrations in multivariate analyses. FSTL3 was independently associated with an adverse cardiometabolic profile. In CKD mice, hepatic mFSTL3 mRNA expression was increased more than 6-fold as compared with controls. Conclusions. Circulating FSTL3 is significantly and independently associated with renal function in both patients with CKD and AKD. Hepatic mFSTL3 mRNA upregulation might contribute to increased FSTL3 levels in CKD. Our results are in agreement with the hypothesis that FSTL3 is eliminated by the kidneys and might counteract adverse activin/myostatin signalling observed in renal dysfunction.
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I N T R O D U C T I O N
Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) are global health burdens and their prevalence has increased over recent decades [1] . Importantly, CVD, T2DM and CKD not only predict mortality as single risk factors, but also influence and contribute to each other [2] . Furthermore, these cardiometabolic disease states are often associated with other facets of metabolic syndrome, including hypertension, obesity and dyslipidaemia [3] .
In the last few years, different cytokines have been introduced that are dysregulated in CVD, T2DM and CKD and are associated with mortality in affected patients. Thus the adipocytokine leptin is an appetite-suppressing and proatherogenic factor that is closely associated with several facets of metabolic syndrome [4] . Furthermore, adipocyte fatty acid-binding protein (AFABP) is an adipocytokine that contributes to metabolic syndrome, atherosclerosis and cardiovascular mortality [5, 6] . Interestingly, both cytokines are increased in CKD [7, 8] and could therefore potentially link CKD with cardiometabolic morbidity and mortality. 
Recently, follistatin-like 3 (FSTL3), also known as follistatinrelated gene protein or follistatin-related protein 3, has been introduced as a novel cytokine that induces insulin resistance and increases visceral fat mass [9] . FSTL3 knockout mice exhibited decreased visceral fat mass and improved glucose tolerance, as well as enhanced insulin sensitivity, as compared with control animals [9] . Mechanistically, FSTL3 is an antagonist of the transforming growth factor b (TGF-b) superfamily [10] , especially activin and myostatin [11, 12] . In their elegant study, Mukherjee et al. [9] suggested that augmented activin and myostatin bioactivity due to FSTL3 deficiency might account for the beneficial metabolic phenotype observed in FSTL3 knockout mice.
In contrast to the extensive animal studies of Mukherjee et al. [9] , human data on the regulation and elimination of FSTL3 is limited. Thus there is no study investigating the role of FSTL3 in patients with cardiometabolic diseases and renal dysfunction. Furthermore, the role of the kidney in FSTL3 regulation has not yet been investigated. Due to its reported molecular weight (i.e. $30 kDa) [13, 14] , renal elimination of FSTL3 is plausible [15] . The route of FSTL3 elimination is of particular interest and importance prior to evaluating the cytokine as a potential target for the treatment of CVD, T2DM and CKD.
In the current study, we therefore investigated FSTL3 regulation in human and murine renal dysfunction in (i) a total of 581 patients with CKD covering the whole spectrum of renal dysfunction ranging from estimated glomerular filtration rate (eGFR) category G1 to G5, (ii) a total of 61 patients before and after elective unilateral nephrectomy as a model of acute kidney dysfunction (AKD) and (iii) a CKD mouse model as compared with control animals. Furthermore, we correlated circulating FSTL3 to clinical and biochemical markers of renal function, glucose and lipid metabolism, as well as inflammation, in both human studies. Our hypothesis was that FSTL3 is eliminated by the kidneys and therefore (i) circulating FSTL3 increases in CKD, with highest levels in eGFR category G5; (ii) circulating FSTL3 increases in AKD after nephrectomy and (iii) FSTL3 mRNA expression is downregulated in CKD mice as compared with control animals.
M A T E R I A L S A N D M E T H O D S
Human studies Study population 1 (CKD). The design of this crosssectional study with inclusion and exclusion criteria has recently been described [8, [16] [17] [18] . In brief, 581 patients (men, n ¼ 338; women, n ¼ 243) were recruited by the Department of Endocrinology and Nephrology, University of Leipzig, as well as from three different outpatient nephrology care units (Hospital St. Georg, Division of Nephrology, KfH Renal Unit, Leipzig; Outpatient Nephrology Care Unit, Leipzig). Patients were classified into eGFR categories G1-G5 according to the Kidney Disease: Improving Global Outcomes guidelines [19] . According to the National Kidney Foundation practice guidelines for CKD [20] , all patients on dialysis therapy were assigned to category G5. The majority of patients on dialysis (n ¼ 218) received haemodialysis (n ¼ 215) and only three patients were on peritoneal dialysis. All blood samples were taken after an overnight fast. In all haemodialysis patients, blood was obtained just before haemodialysis started.
Study population 2 (AKD).
The study design with inclusion and exclusion criteria has recently been described [8, 17, 21] . Briefly, 61 patients (men, n ¼ 44; women, n ¼ 17) were consecutively recruited before elective partial or total unilateral nephrectomy by the Department of Urology, University of Leipzig. In all patients of study population 2, fasting blood samples were drawn before as well as within 30 h after renal surgery.
In both study populations, eGFR was calculated using the CKD Epidemiology Collaboration equation [22] . Anthropometric measures included body mass index (BMI), waist:hip ratio (WHR) and waist:height ratio (WHtR). Homoeostasis model assessment of insulin resistance (HOMA-IR) was calculated as previously described [23] . Both studies were approved by the local ethics committee.
Assays
Serum concentrations of FSTL3 (R&D Systems, Minneapolis, MN, USA; catalogue number DFLRG0), leptin and adiponectin (both Mediagnost, Reutlingen, Germany) were determined in all blood samples with enzyme-linked immunosorbent assays (ELISAs) according to the manufacturers' instructions. Urinary FSTL3 (R&D Systems; catalogue number DFLRG0) and urinary albumin (Exocell, Philadelphia, PA, USA; Albuwell h Albumin) were quantified in a subset of the CKD cohort (n ¼ 386) as well as at the pre-surgical time point of the AKD cohort (n ¼ 53). The sensitivity of the FSTL3 ELISA was 0.009 mg/L. The degree of precision of the ELISA system in terms of the intra-assay and interassay coefficients of variance (%) was <3.5% and 6.5%, respectively. Spike recovery and dilution linearity in serum were in the range of 91-112% and 96-105%, respectively. Furthermore, the ELISA was specific for human FSTL3 and did not cross-react with human activin A and myostatin. The FSTL3 ELISA measures total FSTL3, i.e. free and bound FSTL3. Furthermore, there is a very low level of interference of activin A or myostatin with the FSTL3 immunoassay that is limited to very high concentrations (i.e. 50 ng/mL) of activin A or myostatin. Importantly, circulating levels of both activin A and myostatin in CKD, and even in end-stage renal disease, are a >15-fold lower than 50 ng/mL [24, 25] . Serum creatinine; fasting glucose (FG); fasting insulin (FI); glycated haemoglobin A1c (HbA1c); triglycerides (TG); total, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol and high-sensitivity C-reactive protein (hsCRP) were measured in a certified laboratory by standard methods.
Animal studies
For this study, an animal model of CKD (eNOS À/À C57BLKS db/db mice) was compared with control mice (eNOS À/À C57BLKS), as described previously [26, 27] . All animal experiments were performed in the Medical Experimental Center at the University of Leipzig and approved by the local ethics committee of the state of Saxony (Landesdirektion Leipzig; approval number TVV12/14). Mice were maintained under pathogen-free conditions at 21 6 1 C on a 12-h light/dark cycle (6 AM-6 PM). All
animals had free access to water and a normal pellet diet (V1534; Sniff, Soest, Germany). In all mice, spot urine was collected in the morning every 4 weeks. Urinary albumin and creatinine excretion was determined using Albuwell M and Creatinine Companion kits (Exocell) and albumin:creatinine ratios (ACRs) were calculated. At the age of 24 weeks, mice were sacrificed by exsanguination under deep anaesthesia with ketamine (WDT, Garbsen, Germany) and xylazine (Bayer HealthCare, Wuppertal, Germany). Portions of liver, muscle and kidney, as well as visceral (VAT), subcutaneous (SAT) and brown (BAT) adipose tissue, were snap-frozen in liquid nitrogen for RNA and protein isolation. Mouse FSTL3 mRNA levels were determined relative to acidic ribosomal phosphoprotein P0 (36B4) using quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) and a fluorescent temperature cycler (Roche, Heidelberg, Germany), as described previously [28] . The following primer pairs were used: mFSTL3, TGATGGGCTCCGAGGATTC (sense) and TTATTGCCTGGGTGGGTGAA (antisense); m36B4, AAGCGCGTCCTGGCATTGTCT (sense) and CCGCAGGGGCAGCAGTGGT (antisense).
Effects of pro-inflammatory interleukin-1b (IL-1b) on mFSTL3 expression in AML12 hepatocytes in vitro
Insulin transferin sodium selenite supplement was obtained from Roche Molecular Biochemicals (Mannheim, Germany), dexamethasone and IL-1b were obtained from Sigma Aldrich (Steinheim, Germany). Cell culture reagents were purchased from GE Healthcare (Freiburg, Germany). AML12 cells (American Type Culture Collection, Rockville, MD, USA) were grown and after 48-h starvation, differentiated AML12 hepatocytes were cultured in the presence or absence of 20 ng/mL IL1b. Determination of mFSTL3 mRNA synthesis was done by quantitative real-time RT-PCR. In more detail, 1-mL cDNA was quantified on a LightCycler 480 real-time PCR 96-well thermocycler using LightCycler 480 Probes Master Mix (Roche Diagnostics, Mannheim, Germany) essentially as described previously [29, 30] . Primer pairs of the animal studies were used and mFSTL3 mRNA expression was calculated relative to m36B4, which was used as an internal control due to its resistance to hormonal regulation.
Statistical methods
SPSS software version 20.0 (IBM, Armonk, NY, USA) was used for all statistical analyses in human subjects and tests used are described in the legends of Tables 1-4 and in previous studies from our group [8, [16] [17] [18] . GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA) was used for all statistical analyses in mice and in vitro experiments and tests used are described in the respective figure legends. P-values <0.005 were considered statistically significant in all analyses. 
Study population 1 (CKD)
Circulating FSTL3 levels increase with deteriorating renal function. Baseline characteristics of study population 1 (CKD) divided into the five eGFR categories, G1-G5, are shown in Uni-and multivariate correlations. In univariate correlation analysis, circulating FSTL3 was significantly and positively correlated with age, WHR, WHtR, creatinine, TG, hsCRP, leptin and adiponectin (Table 2 ). In contrast, FSTL3 was negatively and significantly associated with diastolic blood pressure (DBP), eGFR, FG, FI, HOMA-IR, HbA1c, total cholesterol, HDL cholesterol and LDL cholesterol ( Table 2 ). To identify independent associations, multiple linear regression analysis was carried out. Here, eGFR was the strongest and a negative predictor of FSTL3 serum levels after adjustment for age and gender as well as for markers of obesity (i.e. WHR), blood pressure (i.e. DBP), dyslipidaemia (i.e. TG, HDL cholesterol, LDL cholesterol), inflammation (i.e. hsCRP) and glucose homeostasis (i.e. adiponectin) ( Table 2) . Furthermore, age, WHR, hsCRP and adiponectin were independently and positively associated with FSTL3 in multivariate analysis (Table 2 ). In a subset of the cohort comprising 386 patients in all eGFR categories, urinary FSTL3 was strongly associated with serum FSTL3 as well as with markers of renal function, including creatinine, eGFR and urinary albumin (Supplementary data, Table S1 ).
Study population 2 (AKD)
Baseline characteristics of study population 2 (AKD), as well as laboratory parameters before and after renal surgery, are summarized in Table 3 . The median serum concentrations of FSTL3 were not significantly different after nephrectomy [6.7 (4.8-8.6) mg/L] as compared with levels prior to surgery [6.8 (5.2-8.3) mg/l] (P ¼ 0.887) ( Table 3 and Figure 1 ). However, relative changes of FSTL3 (postsurgical:presurgical ratio) were significantly and positively correlated with relative changes in creatinine (ratio), whereas they were negatively correlated with eGFR (ratio) (P < 0.001; Table 4 ). Multivariate regression analysis revealed that relative changes of FSTL3 (ratio) were independently and positively associated with relative changes in creatinine (ratio) even after adjustment for age and gender as well as markers of glucose tolerance (i.e. HbA1c) and fat mass (i.e. leptin) (P < 0.001; Table 4 ). The independent association between FSTL3 (ratio) and impaired renal function was also observed when eGFR (ratio) instead of creatinine (ratio) was included in the multivariate model (standardized b ¼ 0.594, P < 0.001). Interestingly, urinary FSTL3 was correlated with urinary albumin at the presurgical time point (Supplementary data, Table S1 ). Figure 2 summarizes animal data on FSTL3 in mice with CKD (eNOS À/À C57BLKS db/db) as compared with non-diabetic controls (eNOS À/À C57BLKS). As expected, ACR increased dramatically and significantly over time (Figure 2A ) in CKD as compared with control littermates (Figure 2A) . In CKD mice, hepatic mFSTL3 expression was significantly and >6-fold increased as compared with control animals (P < 0.001; Figure 2B ). Furthermore, mFSTL3 expression in muscle was 80% lower in CKD mice as compared with controls (P ¼ 0.006; Figure 2C ). In contrast, no significant differential expression of mFSTL3 was found in the kidney or in different fat depots (i.e. VAT, SAT and BAT) of CKD as compared with control mice (Figure 2D-G) .
Animal experiments
Effects of pro-inflammatory IL-1b on mFSTL3 expression in AML12 hepatocytes in vitro
Treatment of differentiated AML12 hepatocytes with 20 ng/ mL IL-1b for 24 h significantly downregulated mFSTL3 mRNA Figure S1 ). In contrast, no significant change in mFSTL3 mRNA expression could be demonstrated at shorter time points (Supplementary data, Figure S1 ).
D I S C U S S I O N
In the current study, we show for the first time that the insulin resistance-inducing and pro-adipogenic cytokine FSTL3 is significantly upregulated in human CKD and increases with higher eGFR categories covering the whole spectrum of chronic renal dysfunction. In agreement with these findings in CKD, relative changes of circulating FSTL3 are also independently and positively associated with impairment of renal function in a human AKD model. To the best of our knowledge, these are the first human data supporting the hypothesis that FSTL3 is crucially regulated by renal function and possibly eliminated by the kidneys. It is interesting to note in this context that other cytokines involved in the pathophysiology of CVD, T2DM and CKD are also upregulated in acute and chronic renal dysfunction, including progranulin [18] , AFABP [8] and fibroblast growth factor 21 [17] . Furthermore, based on the present results, studies elucidating regulation of circulating FSTL3 in humans need to adjust data to renal function as a potential confounding factor. With regards to the renal effects of FSTL3, it is interesting to note that myostatin plasma levels are increased in an early stage of CKD and potentially contribute to CKD complications, including sarcopaenia [25] . Furthermore, Ren et al. [31] elegantly show that activin A is involved in tubulointerstitial fibrosis in diabetic nephropathy in streptozotocin-induced diabetic rats. Moreover, Agapova et al. [32] demonstrate convincingly that inhibition of activin signalling through a ligand trap for the activin receptor type IIA reverses CKD-induced vascular smooth muscle dedifferentiation and decreases renal fibrosis and proteinuria. Taking these findings into consideration, FSTL3 upregulation seen in our CKD cohort might counteract 
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Baseline characteristics of study population 2 and serum parameters before and after renal surgery. Abbreviations are defined in Table 1 . Values presented as median (25th-75th percentile) or total number (percentage). the adverse effects of activin and myostatin in renal dysfunction and thereby protect the kidneys from further damage. It has to be pointed out that FSTL3 binds activin A and myostatin with high affinity in the circulation [33] . These FSTL3-containing complexes have an increased molecular weight/size of up to $130 kDa [33, 34] , making renal elimination of total FSTL3 less plausible. However, there is some evidence that even proteins with higher molecular weights are present in the urine of patients with Fanconi syndrome [35] . Thus, renal elimination might be possible not only for free FSTL3, but also for activin A-or myostatin-FSTL3 complexes. The source of elevated circulating FSTL3 in human CKD remains to be elucidated in future studies. One obvious mechanism is renal FSTL3 retention due to kidney impairment, as seen for other cytokines, including leptin [36] . In addition or alternatively, upregulated FSTL3 expression in target tissues could contribute to increased circulating levels of the cytokine. It is interesting to note in this context that in our CKD mice, hepatic mFSTL3 mRNA expression is significantly increased as compared with control animals. In contrast, muscle mFSTL3 mRNA expression is downregulated, whereas renal and adipose tissue mRNA expression is unchanged in CKD mice as compared with controls. Our in vitro results suggest that the inflammatory status observed in CKD is not the cause for increased mFSTL3 mRNA expression in hepatocytes. Alternatively, resident macrophages in the liver or factors other than inflammation could contribute, at least in part, to increased hepatic mFSTL3 mRNA expression, resulting in increased serum levels of FSTL3 in CKD. Interestingly, FSTL3 is detectable in urine in our human studies and urinary FSTL3 strongly correlates with serum FSTL3, as well as with markers of renal function, including creatinine, eGFR and urinary albumin, in CKD. Since eGFR and creatinine are more strongly associated with urinary FSTL3 as compared with urinary albumin in our CKD cohort (data not shown), it is tempting to speculate that urinary FSTL3 might be an additional marker of impaired renal function.
Potential metabolic effects of increased FSTL3 levels in CKD remain to be elucidated in future studies. Mukherjee et al. [9] suggest that FSTL3 induces insulin resistance and increases visceral fat mass by inhibiting activin and myostatin bioactivity. It is interesting to note in this context that in our CKD cohort, circulating FSTL3 is also positively and independently associated with an adverse cardiometabolic profile including age, WHR and hsCRP. In accordance with our findings, a Danish study convincingly demonstrates a positive association between FSTL3 and fat mass, as well as low-grade inflammation, in a cohort of 200 patients with different levels of glucose tolerance [37] . Furthermore, FSTL3 concentrations in both serum and synovial fluid are increased and positively correlated with the severity of knee osteoarthritis [38] , a chronic degenerative joint disease commonly associated with a pro-inflammatory status [39] . Taking these findings into consideration, increased FSTL3 in CKD might mediate adverse effects on insulin sensitivity, body fat distribution and inflammation. However, it needs to be pointed out that beneficial metabolic effects have been described for FSTL3, including improved peripheral insulin sensitivity as assessed by an insulin tolerance test [40] , as well as protection from hepatic steatosis and hypertension [9] . Furthermore, both FSTL3 and follistatin, with its three different splicing variants, are able to bind activin and myostatin [11] . However, pathophysiological mechanisms of FSTL3 and follistatin isoforms differ and FSTL3 cannot bind to cell-surface proteoglycans, in contrast with follistatin variants [11, 41] . Thus, future studies need to address the potential different biological role of FSTL3 as compared with follistatin in relation to inflammation and glucose and lipid metabolism in patients with renal dysfunction. This is of particular interest since animal data suggest that body composition and glucose homeostasis are differentially regulated by follistatin and FSTL3 [42] .
Taken together, we show that circulating FSTL3 is significantly increased in human CKD and the cytokine is independently associated with renal function in both patients with CKD and AKD. Animal experiments indicate that induction of mFSTL3 expression in the liver might contribute to increased FSTL3 levels in CKD. Our results are in agreement with the hypothesis that FSTL3 is eliminated by the kidneys and might counteract adverse activin/myostatin signalling observed in renal dysfunction. ) and normalized to m36B4 expression as described in the Materials and Methods section. Results are shown as mean 6 standard error of the mean. P-values were assessed by unpaired Student's t-tests with prior logarithmic transformation. n ! 5 per group. *P < 0.01; **P < 0.001; ***P < 0.0001.
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